Trends in remission rates for rheumatoid arthritis in England and Wales: a population-level cohort study
While national remission rates for early RA have remained stable in England and Wales since 2018, there is marked regional and hospital-level variation, highlighting ongoing inequities in service delivery. Addressing factors beyond referral-to-treatment time-particularly delayed presentation to primary care-is required to improve remission rates.
Authors
- James Galloway (ORCID: https://orcid.org/0000-0002-1230-2781)
- Ella Jackson
- Mark Russell (ORCID: https://orcid.org/0000-0001-8171-7772)
- Joanna Ledingham
- Maryam Adas (ORCID: https://orcid.org/0000-0002-5560-6603)
- Peter Lanyon (ORCID: https://orcid.org/0000-0002-9855-6802)
- Edward Alveyn (ORCID: https://orcid.org/0000-0002-6465-6194)
- Sam Norton (ORCID: https://orcid.org/0000-0003-1714-9963)
- Graham Farrell (ORCID: https://orcid.org/0000-0002-3987-8457)
- Callum Coalwood
- Elizabeth Price (ORCID: https://orcid.org/0000-0003-3042-0201)
Institutions
- Nottingham University Hospitals NHS Trust (GB)
- University of Nottingham (GB)
- King's College London (GB)
- Great Western Hospital (GB)
- Portsmouth Hospitals NHS Trust (GB)
- King's College Hospital NHS Foundation Trust (GB)
- British Society for Rheumatology (GB)
- Lifespan (US)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1093/rheumatology/keaf233
- Citations
- 2
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.34
Funders
- Eli Lilly and Company
- Pfizer
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- National Institute for Health and Care Research
- Department of Health and Social Care
- British Society for Rheumatology
- Public Health England
- Swedish Orphan Biovitrum
- Chugai Pharmaceutical